25/05/2016 02:27:29 1-888-992-3836 (toll free) Free Membership Login
Company name:Astrazeneca
Company Description:A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:AZNTrading Currency:GBX
Market Sector:FE00ISIN:GB0009895292
Market Segment:SET0Share Type:DE
WWW Address:http://www.astrazeneca.com/Description:ORD SHS $0.25
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 3,958.50 mages.advfn.com/imagesnew/2/us/up 58.0 [1.49] 3,961.00 3,962.00 3,906.00 3,964.50 3,878.00 1,985,068
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 50,030.84 1,263.88 0.70 152.49 190.03 25.96 4.80 4,634.00 - 3,746.00

Astrazeneca Key Figures

(at previous day's close)
Market Cap.50,030.84m
Shares In Issue1,263.88m
Prev. Close3,900.50
PE Ratio25.96 
Dividend Yield4.80%
EPS - basic152.49p
Dividend PS190.03p
Dividend Cover- 
Cash Flow PS178.49p
Return On Equity (ROE)15.28%
Operating Margin12.42%
PEG Factor0.20 
EPS Growth Rate127.55%
Dividends PS Growth Rate-%
Net Debt24,008.36m
Gross Gearing69.22%
Quick Assets10,485.63m
Net Working Capital1,848.73m
Intangibles / Fixed Assets81.15%
Turnover PS1,326.77p
Pre-Tax Profit PS164.80p
Retained Profit PS-35.49p
Cash PS335.08p
Net Cash PS-463.36p
Net Tangible Asset Value PS *-860.46p
Net Asset Value PS993.90p
Spread1.00 (0.03%) 

Astrazeneca Balance Sheet

LSE:AZN:Liabilities+EQLSE:AZN:Assets

Share Price Performance

Sample Period HighLow
1 week3,964.503,812.00
4 weeks4,107.503,773.00
12 weeks4,242.003,773.00
1 year4,634.003,746.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week3,945.0013.500.343,887.602.223,887.54
4 weeks4,092.00-133.50-3.263,905.952.433,906.00
12 weeks4,116.50-158.00-3.843,992.372.653,995.16
26 weeks4,468.50-510.00-11.414,179.682.664,153.14
1 year4,425.00-466.50-10.544,204.572.574,187.15
3 years3,450.50508.0014.724,095.712.594,147.73
5 years3,157.00801.5025.393,640.012.663,644.58

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio81.13 
PE Ratio25.96 
Tobin's Q Ratio 0.84 
Tobin's Q Ratio (excl. intangibles)1.94 
Dividend Yield4.80%
Market-to-Book Ratio3.99 
Price-to-Pre-Tax Profit PS24.02 
Price-to-Retained Profit PS-111.52 
Price-to-Cash Flow PS22.18 
Price-to-Sales PS2.98 
Price-to-Net Tangible Asset Value PS-4.61 
Price-to-Cash PS11.81 
Net Working Capital PS146.27 
Price Pct to Working Capital PS27.06%
Earnings Yield3.85%
Average PE18.92 
Years in average5 
PE to PE average137.21%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio59.10%
Debt-to-Equity Ratio1.45 
Debt-to-Equity Ratio (excl. Intgbl)-1.67 
Debt-to-Equity Market Value0.36 
Net Gearing58.84%
Net Gearing (excl. Intangibles)138.13%
Gross Gearing69.22%
Gross Gearing (excl. Intangibles)162.50%
Gearing Under 1 Year24.73%
Gearing Under 1 Year (excl. Intgbl)58.06%
Assets/Equity3.25 
Cash/Equity33.71 
(Liquidity Ratios)
Net Working Capital to Total Assets4.53%
Current Ratio1.18 
Quick Ratio (Acid Test)1.04 
Liquidity Ratio0.42 
Cash & Equiv/Current Assets35.47%
(Solvency Ratios)
Enterprise Value63,960.78m
CFO/Sales0.13 
CFO/Attributable Profit1.18 
CFO/Assets0.06 
CFO/Debt0.08 
Total Debt/Equity Market Value0.56 
Total Debt/Sales1.68 
Total Debt/Pre-Tax Profit13.56 
Total Debt28,243.33m
Total Debt/Net Current Assets15.28%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth3.01%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs6 
Beta (60-Mnth)Beta (36-Mnth)
0.69620.8989
Alpha (60-Mnth)Alpha (36-Mnth)
0.00360.0061

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)6.78%
Return On Assets (ROA)3.23%
Net Profit Margin11.43%
Assets Turnover0.28 
Return On Equity (ROE)15.28%
Return On Investment (ROI)4.43%
Dividend Payout Ratio125.56%
Plowback Ratio-25.56%
Growth from Plowback Ratio-2.57%
Net Income Of Revenues-2.68%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.88 
Fixed Assets Turnover0.40 
Current Assets Turnover0.94 
Net Working Capital Turnover 
Inventory Turnover8.17 
(Other Operating Ratios)
Total Assets-to-Sales3.54 
Debtors-to-Sales56.96%
Debt Collection Period207.89Days

Astrazeneca Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
04 Feb 2016FinalUSX190.0012/31/201412/31/201502/18/201602/19/201603/21/2016280.00
30 Jul 2015InterimUSX90.0012/31/201412/31/201508/13/201508/14/201509/14/2015-
05 Feb 2015FinalUSX190.0012/31/201312/31/201402/19/201502/20/201503/23/2015280.00
31 Jul 2014InterimUSX90.0012/31/201312/31/201408/13/201408/15/201409/15/2014-
06 Feb 2014FinalUSX190.0012/31/201212/31/201302/19/201402/21/201403/24/2014280.00
01 Aug 2013InterimUSX90.0012/31/201212/31/201308/14/201308/16/201309/16/2013-
31 Jan 2013FinalUSX190.0012/31/201112/31/201202/13/201302/15/201303/18/2013280.00
26 Jul 2012InterimUSX90.0012/31/201112/31/201208/08/201208/10/201209/10/2012-
02 Feb 2012FinalUSX195.0012/31/201012/31/201102/15/201202/17/201203/19/2012280.00
28 Jul 2011InterimUSX85.0012/31/201012/31/201108/03/201108/05/201109/12/2011-
27 Jan 2011FinalUSX185.0012/31/200912/31/201002/02/201102/04/201103/14/2011255.00
29 Jul 2010InterimUSX70.0012/31/200912/31/201008/02/201008/04/201009/13/2010-
28 Jan 2010FinalUSX171.0012/31/200812/31/200902/03/201002/05/201003/15/2010230.00
30 Jul 2009InterimUSX59.0012/30/200806/30/200908/05/200908/07/200909/14/2009-
29 Jan 2009FinalUSX150.0012/31/200712/31/200802/04/200902/06/200903/16/2009205.00
31 Jul 2008InterimUSX55.0012/30/200706/30/200808/08/200808/06/200809/15/2008-
31 Jan 2008FinalUSX135.0012/31/200612/31/200702/06/200802/08/200803/17/2008187.00
26 Jul 2007InterimUSX52.0006/30/200606/30/200708/08/200708/10/200709/17/2007-
01 Feb 2007FinalUSX123.0012/31/200512/31/200602/07/200702/09/200703/19/2007172.00
27 Jul 2006InterimUSX49.0012/30/200506/30/200608/09/200608/11/200609/18/2006-
01 Feb 2006FinalUSX92.0012/31/200412/31/200502/08/200602/10/200603/20/2006130.00
29 Jul 2005InterimUSX38.0012/30/200406/30/200508/10/200508/12/200509/19/2005-
27 Jan 2005FinalUSX64.5012/31/200312/31/200402/09/200502/11/200503/21/200594.00
22 Jul 2004InterimUSX29.5012/30/200306/30/200408/11/200408/13/200409/20/2004-
29 Jan 2004FinalUSX54.0012/31/200212/31/200302/18/200402/20/200404/06/200479.50
24 Jul 2003InterimUSX25.5012/30/200206/30/200308/20/200308/22/200310/06/2003-
30 Jan 2003FinalUSX47.0012/31/200112/31/200202/19/200302/21/200304/07/200370.00
25 Jul 2002InterimUSX23.0012/30/200106/30/200208/21/200208/23/200210/07/2002-
31 Jan 2002FinalUSX47.0012/31/200012/31/200102/20/200202/22/200204/08/200270.00
26 Jul 2001InterimUSX23.0012/30/200006/30/200108/22/200108/24/200110/05/2001-
08 Feb 2001FinalUSX47.0012/31/199912/31/200002/21/200102/23/200104/09/200170.00
01 Aug 2000InterimUSX23.0012/30/199906/30/200009/04/200009/08/200010/23/2000-
24 Feb 2000FinalUSX47.0012/31/199812/31/199903/06/200003/10/200004/17/200070.00
03 Aug 1999InterimUSX23.0012/30/199806/30/199909/06/199909/10/199910/25/1999-

Astrazeneca Fundamentals

 31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)31 Dec 2015 (USD)
turnover27,973.00100.00%25,711.00100.00%26,095.00100.00%24,708.00100.00%m
pre tax profit7,718.0027.59%3,267.0012.71%1,246.004.77%3,069.0012.42%m
attributable profit6,297.0022.51%2,556.009.94%1,233.004.73%2,825.0011.43%m
retained profit2,632.009.41%-905.00-3.52%-2,288.00-8.77%-661.00-2.68%m
eps - basic499.00 204.00 98.00 223.00 
eps - diluted498.00 204.00 98.00 223.00 
dividends per share280.00 280.00 280.00 280.00 

Astrazeneca Balance Sheet

 31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)31 Dec 2015 (USD)
LSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:AssetsLSE:AZN:Liabilities+EQLSE:AZN:Assets
 31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)31 Dec 2015 (USD)
ASSETS
fixed assets fixed assets6,089.0011.37%5,818.0010.41%6,010.0010.26%6,413.0010.67%m
intangibles intangibles26,346.0049.21%26,028.0046.56%32,531.0055.52%34,514.0057.40%m
fixed investments fixed investments1,442.002.69%1,482.002.65%1,842.003.14%1,604.002.67%m
current assets - other current assets - other--%--%--%--%m
stocks stocks2,061.003.85%1,909.003.42%1,960.003.34%2,143.003.56%m
debtors debtors9,895.0018.48%11,445.0020.47%9,892.0016.88%9,210.0015.32%m
cash & securities cash & securities7,701.0014.39%9,217.0016.49%6,360.0010.85%6,240.0010.38%m
TOTAL53,534.00100%55,899.00100%58,595.00100%60,124.00100%m
LIABILITIES
creditors - short creditors - short13,903.0025.97%16,051.0028.71%17,330.0029.58%14,869.0024.73%m
creditors - long creditors - long15,679.0029.29%16,595.0029.69%21,619.0036.90%26,746.0044.48%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL29,582.0055.26%32,646.0058.40%38,949.0066.47%41,615.0069.22%m
EQUITY
ord cap, reserves ord cap, reserves23,737.0044.34%23,224.0041.55%19,627.0033.50%18,490.0030.75%m
prefs, minorities prefs, minorities215.000.40%29.000.05%19.000.03%19.000.03%m
TOTAL23,952.0044.74%23,253.0041.60%19,646.0033.53%18,509.0030.78%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Astrazeneca Cash Flow Statement

31 Dec 2012 (USD)31 Dec 2013 (USD)31 Dec 2014 (USD)31 Dec 2015 (USD)
Operating CF6,948.007,400.007,058.003,324.00m
Pre-Financing CF5,089.004,511.0026.00-915.00m
Retained CF166.001,464.00-2,679.00-37.00m

Astrazeneca Brokers

NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Nyenburgh Holding B.V.Market Maker(MME)Broker/DealerNYBBNYENNL2B
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160525 01:27:29